Skip to main content

OR in Public Health: A Little Help Can Go a Long Way

  • Chapter
  • First Online:
Book cover Operations Research and Health Care Policy

Part of the book series: International Series in Operations Research & Management Science ((ISOR,volume 190))

Abstract

When deciding which programs to invest in, public health decision makers face a number of challenges including limited resources, competing objectives (e.g., maximize health, achieve equity), and limited information about uncertain events. Despite these difficulties, public health planners must make choices about which programs they will invest in—and the quality of these choices affects the health benefits achieved in the population. To support good decisions, information about the likely costs and health consequences of alternative interventions is needed. This is where OR-based modeling can play a role: by providing a structured framework that uses the best available evidence, imperfect as it may be, and that captures relevant uncertainties, complexities, and interactions, OR-based models can be used to evaluate the potential impact of alternative public health programs. This chapter describes modeling efforts in which OR has played and can play a role in informing public health decision making. We describe work in three areas: hepatitis B control, HIV control, and bioterrorism preparedness and response. We conclude with a discussion of lessons learned.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Centers for Disease Control and Prevention (2008) Hepatitis B fact sheet. http://www.cdc.gov/ncidod/diseases/hepatitis/b/fact.htm. Accessed 8 Apr 2008

  2. Edmunds WJ et al. (1993) The influence of age on the development of the hepatitis B carrier state. Proc Biol Sci 253(1337):197–201

    Article  Google Scholar 

  3. World Health Organization (2008) Hepatitis B. Fact Sheet No. 204. World Health Organization, Geneva, Switzerland

    Google Scholar 

  4. Centers for Disease Control and Prevention (2007) Progress in hepatitis B prevention through universal infant vaccination—China, 1997–2006. MMWR Morb Mortal Wkly Rep 56(18):441–445

    Google Scholar 

  5. Liu J, Fan D (2007) Hepatitis B in China. Lancet 369(9573):1582–1583

    Article  Google Scholar 

  6. Chinese Ministry of Health (2008) The Ministry of Health conference on planning and hepatitis B immunization, malaria prevention and control work [Chinese]. http://www.gov.cn/xwfb/2008–04/21/content_950425.htm. Accessed 1 Aug 2008

  7. United States Census Bureau (2008) China international database country summary. http://www.census.gov/ipc/www/idb/country/chportal.html#TAB. Accessed 18 Nov 2008

  8. Chen JJ (2008) A model HBV catch-up immunization and education project in Qinghai, China. In: National Immunization Conference

    Google Scholar 

  9. Hutton DW, So SK, Brandeau ML (2010) Cost effectiveness of nationwide hepatitis B catch-up vaccination among children and adolescents in China. Hepatology 51(2):405–414

    Article  Google Scholar 

  10. Hutton DW, Brandeau ML (2013) Too much of a good thing? When to stop catch-up vaccination. Working paper

    Google Scholar 

  11. Gold MR et al. (1996) Cost-effectiveness in health and medicine. Oxford University Press, New York

    Google Scholar 

  12. Hutton DW, So SK, Brandeau ML (2011) Doing good with good OR: supporting cost-effective hepatitis B interventions. Interfaces 41(3):289–300

    Article  Google Scholar 

  13. Custer B et al. (2004) Global epidemiology of hepatitis B virus. J Clin Gastroenterol 38(10 Suppl):S158–S168

    Article  Google Scholar 

  14. McQuillan GM, Coleman PJ, Kruszon-Moran D (1999) Prevalence of hepatitis B virus infection in the United States: the National Health and Nutrition Examination Surveys, 1976 through 1994. Am J Public Health 89(1):14–18

    Article  Google Scholar 

  15. Hutton DW et al. (2007) Cost-effectiveness of screening and vaccinating Asian and Pacific Islander adults for hepatitis B. Ann Intern Med 147(7):460–469

    Google Scholar 

  16. Murray CJ, Lopez A (2002) World Health Report 2002: reducing risks, promoting healthy life. World Health Organization, Geneva, Switzerland, p 186

    Google Scholar 

  17. Owens DK (1998) Interpretation of cost-effectiveness analyses [Editorial]. J Gen Intern Med 13(10):716–717

    Article  Google Scholar 

  18. World Health Organization (2003) Making choices in health: WHO guide to cost-effectiveness analysis. World Health Organization, Geneva, Switzerland

    Google Scholar 

  19. Weinbaum CM, Mast EE, Ward JW (2009) Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. Hepatology 49(5 Suppl):S35–S44

    Article  Google Scholar 

  20. Weinbaum CM et al. (2008) Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recomm Rep 57(RR-8):1–20

    Google Scholar 

  21. Joint United Nations Programme on HIV/AIDS (UNAIDS) (2010) UNAIDS report on the global AIDS epidemic 2010. UNAIDS, Geneva, Switzerland

    Google Scholar 

  22. Open Society Institute (2008) Harm reduction developments 2008. Countries with injection-driven HIV epidemics. Open Society Institute, New York

    Google Scholar 

  23. Samoilov D (2004) Double discrimination: drug users living with HIV/AIDS. HIV AIDS Policy Law Rev 9(3):83–85

    Google Scholar 

  24. World Health Organization (2005) Summary country profile for HIV/AIDS treatment scale-up: Russian Federation, June 2005. World Health Organization, Geneva, Switzerland

    Google Scholar 

  25. Open Society Institute (2004) Breaking down barriers: lessons on providing HIV treatment to injection drug users. Open Society Institute, New York

    Google Scholar 

  26. Long EF et al. (2006) Effectiveness and cost-effectiveness of strategies to expand antiretroviral therapy in St. Petersburg, Russia. AIDS 20(17):2207–2215

    Article  Google Scholar 

  27. Alistar SS, Brandeau ML (2012) Decision making for HIV prevention and treatment scale up: bridging the gap between theory and practice. Med Decis Making 32(1):105–117

    Article  Google Scholar 

  28. Long EF et al. (2006) Оценка эффективности и экономической эффективности стратегии расширенной антиретровирусной терапии в Санкт-Петербурге, Россия. http://www.stanford.edu/dept/MSandE/cgi-bin/people/faculty/brandeau/brandeau.php. Accessed 31 Oct 2011

  29. Joint United Nations Programme on HIV/AIDS (UNAIDS) (2008) Ukraine—National report on monitoring progress towards the UNGASS declaration of commitment on HIV/AIDS. UNAIDS, Geneva, Switzerland

    Google Scholar 

  30. Alistar SS, Owens DK, Brandeau ML (2011) Effectiveness and cost effectiveness of expanding harm reduction and antiretroviral therapy in a mixed HIV epidemic: a modeling analysis for Ukraine. PLoS Med 8(3):e1000423

    Article  Google Scholar 

  31. Alistar SS, Owens DK, Brandeau ML (2011) Результативность и экономическая эффективность расширения программ снижения вреда и антиретровирусной терапии при «смешанной» эпидемии ВИЧ: анализ модели на примере Украины. http://www.plosmedicine.org/attachments/pmed.1000423_Russian.pdf. Accessed 31 Oct 2011

  32. Koplan J (2001) CDC’s strategic plan for bioterrorism preparedness and response. Public Health Rep 116(Suppl 2):9–16

    Article  Google Scholar 

  33. Benson B, McKinney P (2003) Selecting and stocking antidotes to biological/chemical agents. In: Texas Society of Health-Systems Pharmacists Annual Meeting, Austin, TX

    Google Scholar 

  34. Case GG, West BM, McHugh CJ (2001) Hospital preparedness for biological and chemical terrorism in central New Jersey. N J Med 98(11):23–33

    Google Scholar 

  35. Bravata DM et al. (2003) Regionalization of bioterrorism preparedness and response (Evidence report/technology assessment). Agency for Healthcare Research and Quality, Rockville, MD

    Google Scholar 

  36. Bravata DM et al. (2006) Reducing mortality from anthrax bioterrorism: strategies for stockpiling and dispensing medical and pharmaceutical supplies. Biosecur Bioterror 4(3):244–262

    Article  Google Scholar 

  37. Zaric GS et al. (2008) Modeling the logistics of response to anthrax bioterrorism. Med Decis Making 28(3):332–350

    Article  Google Scholar 

  38. Holty JE et al. (2006) Systematic review: a century of inhalational anthrax cases from 1900 to 2005. Ann Intern Med 144(4):270–280

    Google Scholar 

  39. Institute of Medicine Committee on Prepositioned Medical Countermeasures (2011) Prepositioning antibiotics for anthrax. National Academies Press, Washington, DC

    Google Scholar 

Download references

Acknowledgment

This work was supported by grant number R01-DA15612 from the National Institute on Drug Abuse.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Margaret L. Brandeau .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media New York

About this chapter

Cite this chapter

Brandeau, M.L. (2013). OR in Public Health: A Little Help Can Go a Long Way. In: Zaric, G. (eds) Operations Research and Health Care Policy. International Series in Operations Research & Management Science, vol 190. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-6507-2_2

Download citation

Publish with us

Policies and ethics